About "Pharmaceuticals & life science"
The PwC pharmaceuticals and life science practice provides professional services to leading pharmaceuticals and life science organizations.
More about this author
Accounting guidesUS GAAP: Issues and solutions for pharmaceuticals and life sciences industry
11/20/13 | Pharmaceuticals & life science
This publication highlights factors the industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.
- Customer experience in the pharmaceutical sector: Getting closer to the patient
11/19/13 | Pharmaceuticals & life science
As patients exert greater control over their healthcare, drug makers need to master the complexities of consumer behavior to demonstrate value in the new health economy. Consumers are willing to offer feedback that informs who they are, how they behave and how existing biases impact their behavior. Drug makers that tap into this feedback will reach a new level of success.
- Contingent Consideration in a Business Combination
10/16/13 | Pharmaceuticals & life science
This Pharmaceutical and Life Sciences Industry Alert provides guidance on the accounting for contingent consideration arrangements in business combinations.
WebcastMedtech companies prepare for an innovation makeover webcast - October 22, 2013
10/11/13 | Pharmaceuticals & life science
Watch this complimentary webcast where we present the findings from PwC's Health Research Institute's (HRI) new report: Medtech companies prepare for an innovation makeover. This webcast discusses leading industry practices that result in high impact innovation strategies designed to drive business models, management processes and product development efforts.
WebcastPreparing for Serialization and ePedigree in the Pharmaceutical and Biotech Industry Webcast - September 17, 2013
8/15/13 | Pharmaceuticals & life science
Please watch a complimentary webcast featuring Virginia Herold from California Board of Pharmacy and Siobhan O'Bara from GS1 US as featured speakers who provide their perspectives on serialization and ePedigree regulations, and the industry's current state of readiness. PwC provides a brief overview on its approach for helping manufacturers, distributors, and pharmacies.
10Minutes10Minutes on drug value in the New Health Ecosystem
7/31/13 | Pharmaceuticals & life science
Pharmaceutical companies stand ready to be tested in a world where a drug’s success is more closely tied to its performance. The challenges mount with competition from generics and growing pressure to reduce costs. Now, insurers and integrated providers are driven by models that reward health outcomes and cost savings. For success, drug makers are exploring real-world evidence, new payment models, and the right partnerships.
- MoneyTreeTM venture capital funding: Capital crunch
5/22/13 | Pharmaceuticals & life science
The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.
- Medical device excise tax (updated March 28, 2013)
3/29/13 | Pharmaceuticals & life science
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that medical device manufacturers will need to begin accounting for this tax for all sales, other than tax free sales, beginning January 1, 2013 and will need to consider the impact of this tax on their 2013 results.
- New tax law extends research & development tax credit
2/11/13 | Pharmaceuticals & life science
This edition of PwC's Pharmaceutical and Life Sciences Industry Alert reports that the new tax law extends research & development tax credit and provides guidance on accounting for the retroactive reinstatement of the R&D tax credit.
WebcastConflict minerals: What does Dodd-Frank Section 1502 mean for companies in the Life Sciences industry? – February 6, 2013
1/25/13 | Pharmaceuticals & life science
On August 22, 2012 the SEC issued a final rule on conflict minerals pursuant to Dodd-Frank Section 1502. Join us as PwC panelists from our Health Industries practice lead a discussion addressing the rule, what life sciences products are likely to be covered, and what companies should be doing now.
- Potential Accounting Implications of Supreme Court Decision on the Affordable Care Act
5/31/12 | Pharmaceuticals & life science
The Supreme Court heard arguments concerning the Affordable Care Act in March 2012 and expects to issue its decision on the constitutionality of the Affordable Care Act by the end of June 2012. If the law should be invalidated by the Supreme Court, either in whole or in part, there could be significant accounting and financial reporting implications. This PwC Pharmaceutical and Life Sciences Industry Alert focuses on the potential accounting implications of the Supreme Court decision on the Affordable Care Act.
- Greece Debt Restructuring
4/9/12 | Pharmaceuticals & life science
In February 2012, the Greek government announced a debt restructuring which required holders to exchange their two-year and three-year bonds, currently scheduled to mature in December 2012 and 2013, for new non-interest bearing government bonds with longer maturities and a reduced redemption value. This edition of PwC's Pharmaceutical and Life Sciences Industry Alert discusses why pharmaceutical companies will need to evaluate the debt restructuring in order to properly assess the accounting impact of this event.